UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
UNITY Biotechnology Program Update
UNITY Biotechnology (NASDAQ: UBX) is scheduled to host a program update on its lead program, UBX1325, focused on diseases of aging. The update will feature retinal expert Robert B. Bhisitkul, M.D., Ph.D. from UCSF, and will take place on April 24, 2023, at 5:00 a.m. PT/8:00 a.m. ET. The discussion is expected to cover potential therapeutic advancements in age-related ophthalmologic conditions, such as Diabetic Macular Edema (DME) and Age-related Macular Degeneration (AMD).
Investors can access the live webcast on UNITY's website, with a replay available shortly after. The company emphasizes its dedication to developing therapeutics aimed at selectively eliminating or modulating senescent cells to address age-related diseases. However, investors should remain cautious of the inherent risks and uncertainties in the clinical development process.
- Lead program UBX1325 focuses on age-related diseases with potential breakthroughs in DME and AMD.
- The program update aims to provide valuable insights into the therapeutic development pipeline.
- Inherent risks in drug development could impact timelines and outcomes.
- Potential delays due to external factors like COVID-19 may affect clinical trial progress.
Program Update with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., to be held on Monday, April 24 at 5:00 a.m. PT/8:00 a.m. ET
SOUTH SAN FRANCISCO, Calif., April 23, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a program update to discuss its lead program in UBX1325 on Monday, April 24, 2023 at 5:00 a.m. ET/8:00 a.m. ET, with retinal expert and senior clinical advisor Robert B. Bhisitkul, M.D., Ph.D., of University of California San Francisco School of Medicine.
The live webcast can be accessed in the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations” or by clicking here. A replay will be available two hours after the completion of the call and can be accessed in the “Investors & Media” section of our website, under “Events and Presentations.”
About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME, AMD, and other ophthalmologic diseases, the expected timing of the results of the clinical trials in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of UNITY in general, see UNITY’s most recent Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 15, 2023, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.
Media Contact
Evoke Canale
Katherine Smith
Katherine.smith@evokegroup.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
What is the purpose of the UBX1325 program update?
Who will be speaking at the UNITY program update on April 24, 2023?
Where can I access the UNITY program update webcast?
What are the potential risks associated with UBX1325 development?
